GAROFALO STEPHEN A Form SC 13G/A January 19, 2007

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G**

# **Under the Securities Exchange Act of 1934**

(Amendment No.  $\underline{7}$ )\*

# Interleukin Genetics, Inc.

(Name of Issuer)

# Common Stock, \$.001 par value per share

(Title of Class of Securities)

# **458738101**

(CUSIP Number)

# **December 31, 2006**

(Date of Event which Requires Filing of this Statement)

				~	
Charle the ennuenciate	how to decignate	the mule numeriont	to rubiah thia	Cahadula is f	iladı
Check the appropriate	DOX to designate	the rule bursuant	lo winch uns	ochequie is i	nea.

Rule 13d-1(b)

X Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 458738101	13G	Page 2 of 6 Pages

1	NIANCE	OF DEDC	DTIME	DEDCOMO
	NAME	OF KEPU	JK I HNUT	PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

# Stephen A. Garofalo

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*
  - (a) [ ]
  - (b) [ ]
- 3 SEC USE ONLY
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION

# **United States**

5 SOLE VOTING POWER

NUMBER OF 2,368,500

**SHARES** 6 SHARED VOTING POWER

**BENEFICIALLY** 

OWNED BY 864,967

EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON 2,368,500

WITH 8 SHARED DISPOSITIVE POWER

# 864,967

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

# 3,233,467 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\* [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.89% 12 TYPE OF REPORTING PERSON\*

IN

13G

Page 3 of 6 Pages

CUSIP No. 458738101

Item 1.
(a)
Name of Issuer
Interleukin Genetics, Inc.
(b)
Address of Issuer s Principal Executive Offices
·
135 Beaver Street
Waltham, MA 02452
Waldiding Will V2-102
I 2
Item 2.
(a)
Name of Person Filing
Stephen A. Garofalo (the Reporting Person )
(b)
Address of Principal Business Office or, if none, Residence

6 Teal	Court
New Ci	ity, New York 10956-3156
(c)	
Citizens	ship
United	States
(d)	
Title of	Class of Securities
Commo	on Stock, \$.001 par value per share (the Common Stock )
(e)	
CUSIP	Number
458738	101
Item 3.	
	statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a APPLICABLE.
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

CI	121	P	Nο	458	738	101	ı

13G

Page	4	of	6	<b>Pages</b>

- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

## Item 4.

# Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:

As of the date of this filing: The Reporting Person beneficially owns 3, 233,467 shares of the Common Stock of the Issuer as follows, (i) 2,368,500 of these shares are owned directly by the Reporting Person; (ii) 50,000 of these shares are owned by the Reporting Person s spouse; and (iii) 814,967 of these shares are owned by First Global Technology Corp. (First Global). The Reporting Person is the controlling stockholder of First Global and, as such, has the power to vote and dispose of those shares of Common Stock owned by First Global.

(b)

Percent of class: Taking into consideration that 27,201,000 shares are issued and outstanding as reported in the Issuer s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2006 for the quarterly period ended September 30, 2006.

11.89%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote 2,368,500
(ii)
Shared power to vote or to direct the vote <b>864,967</b>
(iii)
Sole power to dispose or to direct the disposition of 2,368,500
(iv)
Shared power to dispose or to direct the disposition of <b>864,967</b>
<i>Instruction</i> . For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

CUSIP No. 458738101	13G	Page 5 of 6 Pages
Item 5.		
Ownership of Five Percent or Less of a Class.		
If this statement is being filed to report the fact that as of beneficial owner of more than five percent of the class of		
Instruction: Dissolution of a group requires a response to	this item.	
Item 6.		
Ownership of More than Five Percent on Behalf of A	nother Person.	
Not Applicable		
Item 7.		
Identification and Classification of the Subsidiary Wl Parent Holding Company.	nich Acquired the Security Being	Reported on By the
Not Applicable		
~ ~		
Item 8.		
Identification and Classification of Members of the G	roup.	
Not Applicable		

Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 458738101 13G Page 6 of 6 Pages

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 17, 2007

By: /s/ STEPHEN A. GAROFALO
Stephen A. Garofalo